anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Bacterial vaginosis (BV) can cause vaginal dysbiosis that may influence general vaginal health and pregnancy complications. Balancing vaginal microbiome using Lactobacillus spp. may be a new way to prevent and treat mild BV. We conducted a randomized, double-blind, placebo-controlled pilot study aimed at evaluating the effect of the product VagiBIOM, a multi-Lactobacillus vaginal suppository, on peri- and premenopausal women with BV in restoring vaginal pH and overall vaginal health by resetting the vaginal microbiome composition. Sixty-six peri- and premenopausal women with BV symptoms were randomized with a 2:1 ratio to be treated with VagiBIOM or placebo suppositories. Vaginal pH, VAS itching score, total Nugent score, and vaginal health index (VHI) were measured. Vaginal microbiome changes before and after the treatment were analyzed by 16S rRNA sequencing and bioinformatics analysis. After 4 weeks of intervention with VagiBIOM or a placebo, the mean score for vaginal pH, VAS itching, and total Nugent score was significantly decreased from the baseline. Compared to the baseline scores, the VHI scores improved significantly following 28-day intervention (p < 0.001). Our results revealed two Lactobacillus species, L. hamsteri, and L. helveticus, as indicator species occurring differentially in the VagiBIOM-treated group. Furthermore, the regression and species network analyses revealed significant bacterial associations after VagiBIOM treatment. Lactobacillus hamsteri was positively associated with the Nugent score and negatively associated with vaginal pH. L. iners and L. salivarius were positively and inversely associated with VHI. As is typical, Bacteroides fragilis was positively associated with vaginal pH and negatively associated with the Nugent score. Interestingly, the Lactobacillus spp. diversity improved after VagiBIOM treatment. The VagiBIOM suppository treatment for peri- and premenopausal women with BV significantly relieved vaginal itching by decreasing vaginal pH and Nugent scores and improving the overall VHI after 4 weeks' intervention. This effect was primarily the result of VagiBIOM improving vaginal Lactobacillus diversity.Trial Registration ClinicalTrials.gov registration: NCT05060029, first registration 09/28/2021: Title: A Pilot Study to Evaluate the Efficacy and Safety of Lactobacillus Species Suppositories on Vaginal Health and pH.
HFNC therapy. The initial flow rate of 50-60 L/min was subsequently adjusted to maintain an oxygen saturation (SpO2) ≥92%. The FiO2 was titrated to maintain the PaO2 between 60 and 80 mmHg.
In patients with type 1 diabetes mellitus, INPEFA significantly increases the risk of diabetic ketoacidosis, a life-threatening event, beyond the background rate. In placebo-controlled trials of patients with type 1 diabetes mellitus, the risk of ketoacidosis was markedly increased in patients who received sodium glucose cotransporter 2 (SGLT2) inhibitors compared to patients who received placebo; this risk may be greater with higher doses of INPEFA. INPEFA is not indicated for glycemic control. 

Type 2 diabetes mellitus and pancreatic disorders (e.g., history of pancreatitis or pancreatic surgery) are also risk factors for ketoacidosis. There have been postmarketing reports of fatal events of ketoacidosis in patients with type 2 diabetes using SGLT2 inhibitors. 

Precipitating conditions for diabetic ketoacidosis or other ketoacidosis include acute febrile illness, reduced caloric intake, ketogenic diet, surgery, insulin dose reduction, volume depletion, and alcohol abuse. 

Signs and symptoms are consistent with dehydration and severe metabolic acidosis and include nausea, vomiting, abdominal pain, generalized malaise, and shortness of breath. Blood glucose levels at presentation may be below those typically expected for diabetic ketoacidosis (e.g., less than 250 mg/dL). Ketoacidosis and glucosuria may persist longer than typically expected. Urinary glucose excretion persists for 3 days after discontinuing INPEFA [see Clinical Pharmacology (12.3)]; however, there have been postmarketing reports of ketoacidosis and glucosuria lasting greater than 6 days and some up to 2 weeks after discontinuation of SGLT2 inhibitors. 

Consider ketone monitoring in patients with type 1 diabetes mellitus and consider ketone monitoring in others at risk for ketoacidosis if indicated by the clinical situation. Assess for ketoacidosis regardless of presenting blood glucose levels in patients who present with signs and symptoms consistent with severe metabolic acidosis. If ketoacidosis is suspected, discontinue INPEFA, promptly evaluate, and treat ketoacidosis, if confirmed. Monitor patients for resolution of ketoacidosis before restarting INPEFA. 

Withhold INPEFA, if possible, in temporary clinical situations that could predispose patients to ketoacidosis. Resume INPEFA when the patient is clinically stable and has resumed oral intake [see Dosage and Administration (2.3)]. 

Educate all patients on the signs and symptoms of ketoacidosis and instruct patients to discontinue INPEFA and seek medical attention immediately if signs and symptoms occur.
FIELD: medicine, narcology, phytotherapy. SUBSTANCE: invention relates to biologically active supplement with hepatoprotective properties used for reduction of alcoholic dependence. Biologically active supplement comprises components of vegetable origin consisting of kudzu (Pueraria) roots powder, kudzu extract, dandelion roots, Canadian golden-seal (Hydrastis) roots, aloe leaves, Gotu Kola, silymarin, gentian roots and pantothenic acid or calcium pantothenate, alpha-lipoic acid, N-acetylcysteine and L-glutathione taken in the mass ratio kudzu roots powder : kudzu extract from 1:0.16 to 1:0.625. The proposed biologically active supplement improves metabolic processes in body, allows to reduce synthesis of acetaldehyde as metabolite of ethanol, promotes to reduction of toxic effect of alcohol and prevention of the development of somatic diseases caused by alcoholic intoxication. EFFECT: enhanced effectiveness and valuable medicinal properties of supplement. 4 cl, 1 tbl
The study will recruit 30-40 young healthy Asian men of Chinese, Malay or Indian descent. Volunteers will visit Clinical Nutrition Research Centre (CNRC) on 1 or 2 occasions: once for consenting and screening procedures (visit 1) and once to follow a 3 hour test session (visit 2). Consenting, screening and the test protocol can take place on the same day or can be scheduled on separate days. In this study the investigators will study the changes in energy expenditure and substrate oxidation when changing posture between sitting and standing. Visit 1 (screening): For screening, potential subjects will come in the morning after an overnight fast. After obtaining informed consent, a series of screening tests will be conducted, including questionnaires (general health, physical activity and eating behaviour), anthropometry (height, weight), blood pressure, resting heart rate, body composition and body proportions (waist circumference, hip circumference, sitting height, leg length, relative leg length, mid-arm circumference, mid-thigh circumference, calf circumference). The physical activity questionnaire will quantify physical activity level. The eating behaviour questionnaire will determine intentional restriction of food intake. Body composition will be measured using an electrical impedance analyser and the BodPod. Body proportions will be measured using a non-stretch measuring tape. Blood pressure and resting heart rate will be measured using an automatic blood pressure monitor. All these methods are non-invasive and do not cause any pain. Visit 2: This test session will last for approximately 3 hours in the morning, during which the following will take place: During each test session, the subject arrive at the centre between 8:00 and 9:00 in the morning after an overnight fast and has been instructed to avoid any physical activity/exercise and alcohol on the day prior to the test. The session will start after the subject enter the whole body calorimeter. The first 45 minutes after entering, resting metabolic rate will be measured. Therefore, the subject will lie down comfortably on a bed in a supine position. Over the following 60 minutes the subject will alternate a sitting and standing position every 15 minutes based on the researchers instructions. The subject will then receive a drink and snack to consume and there will be a 15 minute break in which the subject can take a toilet break if necessary. The break will be followed by a second sequence of 60 minutes in which the subject alternates a sitting and standing position every 15 minutes. After this subject will leave the whole body calorimeter and is free to go home.
The starting dose of nilotinib was same as the last dose given in the parent nilotinib study. After this, the dose of nilotinib was based on the investigator's judgment. The total daily dose was up to 800 mg.
Both the measurement age of a longitudinal trait and the common pre-sampling procedures used in beef cattle herds may affect the identification of a functional candidate gene (FCG) that is potentially associated with a trait. To identify the FCG that takes part in the genetic control of body weight at five different ages in a beef cattle population with and without sequential sampling, the animals were weighed at different measurement events, around 330, 385, 440, 495 and 550 days old. Genetic parameters were estimated for body weight at each age using a single trait (STM) and a random regression model (RRM). In addition, two different databases were used to estimate the genetic parameters: the first (DB100) was formed by all animals that were weighed in the five measurement events, and the second (DB70) has records of the same population, considering that 70% of the heaviest animals were selected after each measurement event. For DB100, genome-wide association studies (GWAS) were performed with 21,667 SNP markers to identify genomic windows that explained at least 1% of the genetic variance. Additionally, prioritization analyses were performed and FCGs were selected. We associated seven different FCGs with body weight at different ages. Among them, the gene DUSP10 was suggested as FCG in all five ages evaluated. Genetic parameters estimated for body weight using DB100 were similar when STM and RRM were applied. However, when DB70 was used as phenotypic data, there were differences between the two models. When the STM was applied, there were differences between the genetic parameters estimated for body weight when DB100 or DB70 were used as sources of phenotypes, but not for the estimates obtained with RRM. The importance of each gene for animal growth can change at different ages, and different genes may be more relevant to body weight at each different growth stage for beef cattle. Besides, sequential sampling can affect the GWAS results of a longitudinal trait. The age of the animal when a longitudinal trait is measured and pre-sampling can also contribute to inconsistencies in GWAS results for body weight in beef cattle, depending on the time when that data were collected, and consequently on the identification of FCG between studies, even when models that consider a covariance structure are used.
PURPOSE:To obtain the titled granule, capable of sustaining the blood level without deteriorating the absorbability and useful as an antihypertensive agent sufficiently effective by one administration a day, by adding a solution of a water-insoluble substance in an organic solvent to a mixture of prazosin with a dissolution accelerating substance and excipient and granulating the resultant blend. CONSTITUTION:A sustained release granule of prazosin, obtained by adding a solution of a water-insoluble substance dissolved in an organic solvent to a mixture of prazosin with a dissolution accelerating substance, e.g. enteric base, cyclodextrin, nonionic surfactant, etc.) and excipient and granulating the resultant blend and having nondisintegrating property. Ethyl cellulose having 5-100cP viscosity at 20 deg.C and 44-51wt% ethoxy group content, hardened oil, etc., may be preferred for the water-insoluble substance, which forms a drug holding structure and prevents the disintegration of the granule in digestive juice. The dissolved prazosin is sustainedly released since it diffuses interstices between the water-insoluble substance in a weaving way.
Chronic obstructive pulmonary disease (COPD) is a leading cause of global death. As a molecule beyond adhesion, CD146 is involved in COPD pathogenesis. However, the mechanisms of CD146 in COPD remain largely elusive. We hypothesized that CD146 regulates the production of matrix metalloproteinase-9 (MMP-9) in macrophages and thereby contributes to COPD. Here, we constructed a murine model of COPD using lipopolysaccharide (LPS) and porcine pancreatic elastase (PPE). In COPD-like mice, LPS and PPE decreased the pulmonary expression of CD146. MMP-9 expression and bioactivity were increased in CD146 knockout COPD-like mice. In vitro, LPS decreased CD146 expression in macrophages. With or without LPS challenge, CD146-defective macrophages produced more MMP-9. Transcriptome analysis based on next-generation sequencing (NGS) revealed that S100A9 regulated MMP-9 production in CD146-defective macrophages. Targeting S100A9 with paquinimod decreased lung inflammation and alleviated alveolar destruction in COPD-like mice. Collectively, our study suggests that CD146 negatively regulates MMP-9 production in macrophages via the S100A9 pathway in COPD.
Described herein are copolymers, and methods of making and utilizing such copolymers.  Such copolymers have at least two blocks: a first block that has at least one unit that is hydrophilic at physiologic pH, and a second block that has hydrophobic groups. This second block further has at least one unit with a group that is anionic at about physiologic pH. The described copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the copolymer is endosomolytic.
IGROOVE is an individually randomized group treatment trial that is controlled and single-blind. It will enroll adults aged 65 years and older who are low-active, report a Cognitive Change Index score ≥16, do not meet criteria for mild cognitive impairment or dementia, are healthy enough to complete repeated graded exercise testing (GXT), and have no contraindications for magnetic resonance imaging (MRI). Randomization will be assessed to ensure equal distribution across study arms for these sex and body mass index (BMI) and will be stratified if necessary. New participants will be rolled into the intervention every 6 weeks. Data collection will take place at Atrium Wake Forest Baptist Health. Interventions will consist of dance classes or music appreciation classes designed and taught by local experts, and will take place in community sites, such as local dance studios, community centers, community gyms or churches. All intervention sites selected will be handicap accessible, well-lit, have appropriate flooring for safe dance movement, and access to sturdy chairs without wheels or arms.
BACKGROUND: There has been a growing interest in pathologic spine-hip relations (PSHR) in current literature, with the aim of reducing the risk of prosthetic impingement, dislocation, and edge loading in total hip arthroplasty (THA). The primary objective of this review is to determine the effect of different PSHR on primary THA outcomes and complication profile. The secondary objective is to stratify the risk of different subgroups of PSHR patients.
METHODS: A systematic review of the literature was performed in accordance with PRISMA guidelines. Randomised controlled trials, comparative cohort studies and case-control studies comparing outcomes and complication rates of primary THA in patients with and without a PSHR (spinal fusion; degenerative spinal conditions determining stiff spine and/or spinal misalignment) were included. The quality of the included studies and the risk of bias were assessed. The revision rate, complications, and clinical and radiological data were analysed. Complications included: aseptic loosening (AL), periprosthetic joint infections (PJI), hip dislocations and periprosthetic fractures (PF).
RESULTS: Fifteen articles were included with 3.306.342 THAs. The mean follow-up (FU) was 31.4 ± 21.7 months. The population was divided into three subgroups: spinal fusion patients (48.315 THAs); non-fused patients with spinal stiffness (106.110 THAs); non-fused patients with normal spines (3.151.917 THAs). A statistically significant risk stratification was observed about dislocation rate (5.98 ± 6.9% SF, 3.0 ± 1.9% non-SF Stiff and 2.26 ± 1.4% non-SF; p = 0.028). Similarly, about THA revision rate, a statistically significant risk stratification was also observed (7.3 ± 6.8% SF, 6.4 ± 3.1% non-SF Stiff and 2.7 ± 1.7% non-SF; p = 0.020). No statistically significant difference was observed when analysing AL, PJI and PF.
CONCLUSION: A statistically significant risk stratification of dislocation and revision rate was observed in the different PHSR, as theorised by the Bordeaux classification. Fused patients present a higher risk, degenerated and/or stiff spine an intermediate risk and mobile spines a lower risk profile. A standardised approach to THA candidate patients must consider the possible PSHR to improve clinical outcomes and reduce adverse events of THA.
The invention concerns to area of pharmacy, biological physics and biodiagnostics, more exactly to development of preparations having ability of magnetic-resonance exposure on micro- and macro organisms with the purpose of activation and protection of their vital activity in conditions of ecological environment at the expense of individual selection of such preparations with the help of the special device. The problem of stability of exposure on biological object with the simple and very habitual for use, universalised, portable, marked if necessary, agent of activation of vital activity of biological object at an ecological level is not solved in any known development. Therefore the first task of the present invention is the creation of universal portable preparation for activation of vital activity of biological object with the help of the physiological carrier capable to be marked, to work in a wide range of an electromagnetic field (EMF) and to keep stable initial properties for a long time during storage. Other task is the creation of a similar preparation capable to work in a wide spectrum of a variable magnetic field (VMF). Both types of preparations are capable to activate the vital activity of organisms, intensifying energetic activity of organism, including accelerating elimination of the harmful foreign agents. Those or other preparations are chosen with the help of the magnetic resonance device capable to find out the foreign agent in the organism being investigated.
Lean, healthy control subjects. Volunteers will be matched for sex and age 21-55 years old. Ethnicities studied will be self-reported. We will attempt to match on race/ethnicities with equal numbers of non-Hispanic/Latinos and Hispanics/Latinos.
The present invention discloses a nutritional health-care medicated food powder. The nutritional health-care medicated food powder includes medicinal materials and edible materials. The medicinal materials and edible materials. The medicinal materials includes ginsengs, radix polygalae, poria cum radix pini, acorus aclamus, radix astragali, lucid ganoderma, angelica sinensis, ossa draconis and oysters. The edible ingredients include millet, walnut kernels, red dates, and brown candy. The recipe screens out combinations which can supplement brain nutrition, and are green and free of any additives through a large number of experiments. The nutritional health-care medicated food powder contains a variety of beneficial ingredients for brain strengthening, such as proteins, lipids (mainly lecithin), vitamin B1, niacin, unsaturated fatty acids, antioxidants, etc. can provide adequate nutrition for the brains in a long-term consumption, has promotion functions for growths of brain nerves, cells and myelin sheath, and repair of brain repair, promotes the comprehensive development of the brains, plays the functions of supplementing brains and benefiting intelligent, enhances memory and slows down the aging of brain cells, can alleviate the diseases caused by a variety of brain cell slow growth or aging, and is suitable for pregnant women.
PURPOSE:A gelatinous ointment, consisting of a silicone oil having a specific viscosity and perfluoro organic compound having a specific molecular weight, having high oxygen solvency and remedial action on peripheral ulcer, e.g. decubital ulcer or crural ulcer and useful also as a base for another drug. CONSTITUTION:A gelatinous ointment prepared by incorporating 1pt.wt. silicone oil having preferably 400-500cSt viscosity (at ordinary temperature) with a perfluoro organic compound having 1,200-2,500 molecular weight. The silicone oil is preferably a fluorine-based silicon oil. The perfluoro organic compound is preferably a perfluoropolyether compound. The ointment has high oxygen solvency, improved remedial action on peripheral ulcer and low toxicity and is capable of enhancing the drug effect of another drug, e.g. antimicrobial agent or fibrinolytic agent, by the oxygen supplying ability thereof and useful as a base.
<P>PROBLEM TO BE SOLVED: To provide a method for stabilizing nanoemulsified particles, and to provide skin care preparations containing stabilized nanoemulsified particles, and particularly when physiologically active substances are included in the particles, to provide skin care preparations highly effective in antioxidation, skin brightening, skin wrinkle inhibition, skin moisturizing, dekeratinization, protein synthesis, etc. depending on the kinds of physiologically active ingredients included therein because of also improving the stability of these physiologically active substances.  <P>SOLUTION: The method for improving the stability of nanosize-emulsified particles of several to several tenth nanometers produced using one or more polyglycerol fatty acid esters as emulsifier involves using a hydroxycarboxylic acid ester. By this method, the stability of the emulsified particles can be improved by adding the hydroxycarboxylic acid ester at 0.001-20 time(s) the total weight of the polyglycerol fatty acid ester(s). Besides, this method enables the skin care preparations compounded with physiologically active ingredients respectively to be provided.  <P>COPYRIGHT: (C)2007,JPO&INPIT